CoChat
Sign Up
Cited by 197Diabetes Management and ResearchDiabetes Management and EducationDiabetes Treatment and Management

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Hirsch, Irl B., Bode, Bruce W., Garg, Satish, Lane, Wendy S., Sussman, Allen, Hu, Peter, Santiago, Olga M., Kolaczynski, Jerzy W., for the Insulin Aspart CSII/MDI Comparison Study Group·2005·Diabetes Care
DOI 10.2337/diacare.28.3.533
Open this paper in CoChat — free account

Abstract

OBJECTIVE—Multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine was compared with continuous subcutaneous insulin infusion (CSII) with aspart in type 1 diabetic patients previously treated with CSII. RESEARCH DESIGN AND METHODS—One hundred patients were enrolled in a randomized, multicenter, open-label, crossover study. After a 1-week run-in period with aspart by CSII, 50 subjects were randomly assigned to MDI therapy (aspart immediately before each meal and glargine at bedtime) and 50 subjects continued CSII. After 5 weeks of the first treatment, subjects crossed over to the alternate treatment for 5 weeks. During the last week of each treatment period, subjects wore a continuous glucose monitoring system for 48–72 h. RESULTS—Mean serum fructosamine levels were significantly lower after CSII therapy than after MDI therapy (343 ± 47 vs. 355 ± 50 μmol/l, respectively; P = 0.0001). Continuous glucose monitoring profiles over a 24-h time period showed that glucose exposure was 24 and 40% lower for CSII than MDI as measured by area under the curve (AUC) glucose ≥80 mg/dl (1,270 ± 742 vs. 1,664 ± 1,039 mg · h · dl−1; P < 0.001) and AUC glucose ≥140 mg/dl (464 ± 452 vs. 777 ± 746 mg · h · dl−1, CSII vs. MDI, respectively; P < 0.001). Similar percentages of subjects reported hypoglycemic episodes (CSII: 92%, MDI: 94%) and nocturnal (12:00 a.m. to 8:00 a.m.) hypoglycemic episodes (CSII: 73%, MDI: 72%). Major hypoglycemia was infrequent (CSII: two episodes, MDI: five episodes). CONCLUSIONS—In a trial of short duration, CSII therapy with insulin aspart resulted in lower glycemic exposure without increased risk of hypoglycemia, as compared with MDI with insulin aspart and glargine.

Overview

Integrity signals

Registry

Crossref · 10.2337/diacare.28.3.533

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 10

  1. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22: 801–805, 1999 · DOI
  2. Anderson JH, Brunelle RL, Koivosto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R, Multicenter Insulin Lispro Study Group: Reduction of postprandial hyperglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265–270, 1997 · DOI
  3. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666–1671, 2000 · DOI · Paper page
  4. Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25:593–598, 1996 · DOI
  5. Reynolds RL: Reemergence of insulin pump therapy in the 1990s. South Med J 93:1157–1161, 2000 · DOI
  6. Bode BW, Strange P: Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 24:69–72, 2001 · DOI
  7. Tsui E, Barnie A, Ross S, Parkes R, and Zinmann B: Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 24:1722–1727, 2001 · DOI
  8. Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber J-P, Study Group for the Development of Pump Therapy in Diabetes: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 23:1232–1235, 2000 · DOI
  9. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ, the Dutch Insulin Pump Study Group: A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25:2074–2080, 2002 · DOI
  10. World Medical Association declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926, 1997 · DOI

Cited by

Sorted by citations

Metadata

Authors
Hirsch, I. B., Bode, B. W., Garg, S., Lane, W. S., Sussman, A., Hu, P., Santiago, O. M., Kolaczynski, J. W., & for the Insulin Aspart CSII/MDI Comparison Study Group
Affiliations
  • University of Washington (US)
  • Atlanta Diabetes Associates (US)
  • Barbara Davis Center for Childhood Diabetes, Denver, Colorado
  • Mountain Diabetes and Endocrine Center (US)
  • Rainier Clinical Research Center (US)
  • Novo Nordisk Pharmaceuticals, Princeton, New Jersey
  • University of Medicine and Dentistry of New Jersey (US)
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2005-03-01
Volume
28
Issue
3
Pages
533-538
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.28.3.533
OpenAlex
W2105346472
Cited by
197
References
4
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 7 · 2016: 9 · 2015: 15 · 2014: 12 · 2013: 12 · 2012: 15
FWCI
9.49
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
insulin pump therapy, insulin aspart, multiple daily insulin injections, insulin glargine, type 1 diabetes, glycemic exposure, hypoglycemia, serum fructosamine, continuous glucose monitoring, insulin therapy switching, glycemic control, nocturnal hypoglycemia, basal insulin, bolus insulin, glycemic variability
MeSH terms
Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Drug Administration Schedule, Female, Glycated Hemoglobin, Humans, Insulin, Insulin Infusion Systems, Male, Biomarkers, Body Mass Index, Fructosamine, Insulin, Long-Acting, Insulin Aspart

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review